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PURPOSE  
We investigated retrospectively the clinical use of a human acellular collagen matrix (HACM) 
for a dura mater substitute. It was previously demonstrated that decellularization and 
viral/bacterial inactivation improved in vitro/in vivo biocompatibility and safety of this device.   
 
METHODS  
HACM was formed from human fascia lata which was chemically and physically treated. One 
human tissue donor provided 2 fascia lata and then 4 HCAM of 10-50 cm². In our study, 130 
patients were treated with HACM between 2003 until 2007. Clinical signs and parameters of 
infection (CRP) and inflammation (White Blood Cell count (WBC) were assessed at: (i) prior, 
(ii) early (1 week after the operation) and (iii) later (> 1 month) post-implantation. Medical 
imagery (CT-Scan, MRI) was also achieved. 
Statistical methods: The test applied for analysis of contingence tables was χ² or Fisher 
test. To compare means, analysis of variance (ANOVA) test has been run supplemented by 
the Bonferroni correction or the nonparametric Kruskal-Wallis test. Analysis of repeated 
measures was performed by using pair t-test or the nonparametric Wilcoxon test. 
 
RESULTS  
Among these cases, the ratio male/ female was 63/67 with a mean age of 45.4 years (range: 
0.25-84). The average follow-up period was 11.75 ± 12.10 months (range: 1-44 months). The 
HACM was applied for cerebral tumours (52.3% of cases); traumatisms (1.5%); 
malformations (43.8%); neuralgias (2.3%). A range of 10 to 50 cm² of HACM was used to 
cure dura-mater defect. No significant correlation was found between clinical indications and 
the HACM size. An overall complication of 2.3% was observed in the total follow-up study. 
HACM leakage was essentially found in malformation indications at pre-operative time. An 
inflammation was elicited at the early post-implantation time by a significant increase of CRP 
and WBC in comparison to pre-transplantation (4.90 vs. 0.20; 11.48 vs. 8.77 for CRP and 
WBC, p<0.005, respectively). A complete return to normal values was found after long-term 
course of implantation (p<0.005).   
 
CONCLUSIONS  
This study confirms, in a large cohort of patients, that human processed tissue is a fully 
applicable and safe device to cure dura-mater defect.  
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